<DOC>
	<DOCNO>NCT01584388</DOCNO>
	<brief_summary>The primary objective study evaluate safety effectiveness rituximab IgG4-RD .</brief_summary>
	<brief_title>Rituximab IgG4-related Disease : A Phase 1-2 Trial</brief_title>
	<detailed_description>This two-center trial enroll total 30 patient IgG4-RD . The two participate site Massachusetts General Hospital ( Boston , MA ) Mayo Clinic ( Rochester , MN ) . All patient receive rituximab 1 gram intravenously time two dos , separate approximately 15 day . The primary efficacy outcome - disease remission successful completion glucocorticoid taper - assessed six month . Patients follow protocol additional six month measurement primary outcome .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Retroperitoneal Fibrosis</mesh_term>
	<mesh_term>Sialadenitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Patients include trial base follow diseasespecific criterion : Age 18 old Diagnosis IgG4RD , base upon either pathological criteria* ( undergone biopsy ) clinical criterion . ** The criterion pathological clinical diagnosis specify . The subject either steroidnaive , relapse , steroid dependent , refractory steroid . Subjects steroid dependent refractory eligible enrollment steroid dose increase past 2 week , treat physician plan withdraw steroid completely ( dose taper ) within 8 week start rituximab . Pathological diagnosis : Histopathologic feature consist lymphoplasmacytic infiltrate storiform fibrosis within involved organ . Other histopathologic feature consistent IgG4RD ( e.g. , obliterative phlebitis ) may present require . Either IgG4/IgG plasma cell ratio &gt; 50 % within affected organ 10 IgG4bearing plasma cell per highpower field . All patient pathologic diagnosis specimen review pathology investigator . **Clinical diagnosis : â€¢ Organ involvement pattern consistent IgG4RD . This must include dysfunction one follow organ : pancreas ( autoimmune pancreatitis ) ; salivary gland ( chronic sclerosing sialadenitis ) ; lacrimal gland ; orbital pseudotumor ; kidney ; lung ; lymph node ; meninges ; aorta ( include aortitis/periaortitis and/or retroperitoneal fibrosis ) ; thyroid gland ( Riedel 's thyroiditis ) . If patient enrol clinical diagnosis alone , diagnosis must accompany image find compatible IgG4RD 1.5fold elevation serum IgG4 concentration . Patients exclude study base follow criterion : DiseaseSpecific Concerns : Excessive fibrosis within organ , disease response rituximab would expect . General Medical Concerns : Pregnancy ( negative serum pregnancy test perform woman childbearing potential within 7 day treatment ) , lactate . Inability comply study and/or followup procedure . RituximabSpecific Concerns : History HIV . Presence active infection . New York Heart Association Classification III IV heart disease ( See Appendix D ) . Concomitant malignancy previous malignancy within last five year , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix . At Investigator 's discretion , receipt live vaccine within 4 week prior randomization . Positive hepatitis B C serology consider potential exclusion criterion . Hepatitis B screen include hepatitis B antibody surface antigen patient risk factor . For patient risk factor previous history hepatitis B , add core antibody eantigen . Allergies : History severe allergic reaction human chimeric monoclonal antibody murine protein . Uncontrolled disease : They show evidence uncontrolled disease , include drug alcohol abuse , could interfere participation trial accord protocol . History antihuman antichimeric antibody formation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Type 1 autoimmune pancreatitis</keyword>
	<keyword>IgG4-related sclerosing cholangitis</keyword>
	<keyword>Chronic sclerosing sialadenitis</keyword>
	<keyword>Lacrimal gland</keyword>
	<keyword>Orbital pseudotumor</keyword>
	<keyword>IgG4-related tubulointerstitial nephritis</keyword>
	<keyword>Lymphadenopathy</keyword>
	<keyword>Pachymeningitis</keyword>
	<keyword>Aorta</keyword>
	<keyword>Peri-aortitis</keyword>
	<keyword>Retroperitoneal fibrosis</keyword>
	<keyword>Riedel 's thyroiditis</keyword>
</DOC>